Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 4 boards, counting each seat separately. Longest: Atara Biotherapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Neumora Therapeutics Inc. May 27, 202694.4%
-
Atara Biotherapeutics Inc. June 10, 202584.9%
-
Ultragenyx Pharmaceutical Inc. May 15, 202586.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 9, 2026 | Atara Biotherapeutics Inc. | Grant or award | +12,000 | — | — |
| May 14, 2026 | Ultragenyx Pharmaceutical Inc. | Grant or award | +7,751 | — | — |
| Jun 10, 2025 | Atara Biotherapeutics Inc. | Grant or award | +7,828 | — | — |
| May 15, 2025 | Ultragenyx Pharmaceutical Inc. | Grant or award | +5,740 | — | — |
| Oct 18, 2024 | Neumora Therapeutics Inc. | Option exercise | +6,205 | $8.79 | $54,542 |
| Oct 18, 2024 | Neumora Therapeutics Inc. | Option exercise | +7,844 | $2.52 | $19,767 |
| Oct 18, 2024 | Neumora Therapeutics Inc. | Open-market sale | −14,049 | $17.03 | $239,254 |
| Oct 17, 2024 | Neumora Therapeutics Inc. | Option exercise | +3,783 | $8.32 | $31,475 |
| Oct 17, 2024 | Neumora Therapeutics Inc. | Option exercise | +1,800 | $8.79 | $15,822 |
| Oct 17, 2024 | Neumora Therapeutics Inc. | Option exercise | +2,156 | $2.52 | $5,433 |
| Oct 17, 2024 | Neumora Therapeutics Inc. | Open-market sale | −7,739 | $17.01 | $131,640 |
| Jun 18, 2024 | Ultragenyx Pharmaceutical Inc. | Grant or award | +5,345 | — | — |
| Jun 13, 2024 | Neumora Therapeutics Inc. | Grant or award | +20,100 | — | — |
| Mar 31, 2024 | Atara Biotherapeutics Inc. | Grant or award | +150,000 | — | — |
| Mar 7, 2024 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −2,550 | $50.89 | $129,770 |
Questions about Matthew K. Fust
What boards is Matthew K. Fust on?
Matthew K. Fust sits on the boards of Atara Biotherapeutics Inc., Electra Therapeutics Inc., Neumora Therapeutics Inc. and Ultragenyx Pharmaceutical Inc.
How long has Matthew K. Fust served on boards?
Our records show at least 10 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.